Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

Swati Sikaria; Josefine Heim-Hall; Elizabeth H. Diaz; Ronald Williams; Kamelesh Sankhala; Brenda Laabs; Monica Mita

doi:10.1007/s11523-013-0267-8

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

Swati Sikaria
, Josefine Heim-Hall
, Elizabeth H. Diaz
, Ronald Williams
, Kamelesh Sankhala
, Brenda Laabs
, Monica Mita

Producción científica: Article › revisión exhaustiva

Idioma original	English (US)
Páginas (desde-hasta)	73-79
Número de páginas	7
Publicación	Targeted Oncology
Volumen	9
N.º	1
DOI	https://doi.org/10.1007/s11523-013-0267-8
Estado	Published - mar 2014

ASJC Scopus subject areas

Pharmacology (medical)
Oncology
Cancer Research

Acceder al documento

10.1007/s11523-013-0267-8

Otros archivos y enlaces

Citar esto

Sikaria, S., Heim-Hall, J., Diaz, E. H., Williams, R., Sankhala, K., Laabs, B., & Mita, M. (2014). Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. Targeted Oncology, 9(1), 73-79. https://doi.org/10.1007/s11523-013-0267-8

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. / Sikaria, Swati; Heim-Hall, Josefine; Diaz, Elizabeth H. et al.
En: Targeted Oncology, Vol. 9, N.º 1, 03.2014, p. 73-79.

Producción científica: Article › revisión exhaustiva

Sikaria, S, Heim-Hall, J, Diaz, EH, Williams, R, Sankhala, K, Laabs, B & Mita, M 2014, 'Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor', Targeted Oncology, vol. 9, n.º 1, pp. 73-79. https://doi.org/10.1007/s11523-013-0267-8

Sikaria S, Heim-Hall J, Diaz EH, Williams R, Sankhala K, Laabs B et al. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. Targeted Oncology. 2014 mar;9(1):73-79. doi: 10.1007/s11523-013-0267-8

@article{34b9f3533a794d909ddf85ea26fae3e8,

title = "Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor",

keywords = "IGFR inhibitor, Tenosynovial giant cell tumor, mTOR inhibitor",

author = "Swati Sikaria and Josefine Heim-Hall and Diaz, \{Elizabeth H.\} and Ronald Williams and Kamelesh Sankhala and Brenda Laabs and Monica Mita",

year = "2014",

month = mar,

doi = "10.1007/s11523-013-0267-8",

language = "English (US)",

volume = "9",

pages = "73--79",

journal = "Targeted Oncology",

issn = "1776-2596",

publisher = "Adis",

number = "1",

}

TY - JOUR

T1 - Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

AU - Sikaria, Swati

AU - Heim-Hall, Josefine

AU - Diaz, Elizabeth H.

AU - Williams, Ronald

AU - Sankhala, Kamelesh

AU - Laabs, Brenda

AU - Mita, Monica

PY - 2014/3

Y1 - 2014/3

KW - IGFR inhibitor

KW - Tenosynovial giant cell tumor

KW - mTOR inhibitor

UR - https://www.scopus.com/pages/publications/84899532050

UR - https://www.scopus.com/pages/publications/84899532050#tab=citedBy

U2 - 10.1007/s11523-013-0267-8

DO - 10.1007/s11523-013-0267-8

M3 - Article

C2 - 23430345

AN - SCOPUS:84899532050

SN - 1776-2596

VL - 9

SP - 73

EP - 79

JO - Targeted Oncology

JF - Targeted Oncology

IS - 1

ER -